n = 337, median [IQR] (range) or n (%) | |
---|---|
Demographics | |
Age at enrolment (years) | 37 [28, 48] (18, 74) |
Age at diagnosis (years) | 26 [19, 38] (1, 69) |
Disease duration (years) | 7 [3, 13] (0, 36) |
Study duration (years) | 3.2 [1.6, 3.4] (0, 4.3) |
Female | 325 (96.4%) |
Current smoker at enrolment | 3 (0.9%) |
Family history of SLE | 25 (7.4%) |
Education level | |
Primary | 83 (24.8%) |
Secondary | 96 (28.7%) |
Tertiary | 156 (46.6%) |
Medications use | |
Prednisolone ever | 319 (94.7%) |
TAM Prednisolone dose | 5.8 [3.7, 9.3] (0, 61) |
Anti-malarials ever | 129 (38.3%) |
Immunosuppressants ever | 284 (84.3%) |
Clinical indicators | |
TAM PGA | 0.4 [0.3, 0.7] (0.2, 1.9) |
TAM SLEDAI-2K | 3.5 [2.0, 5.6] (0, 20) |
Organ damage score | 1 [0, 1] (0, 6) |
Flare (mild/moderate/severe) ever | 189 (56.1%) |
Organ damage present | 176 (52.2%) |
Achieved LLDAS ever | 272 (80.7%) |